Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
Canada
Clinical Trial Site, Edmonton Clinical Trial Site, Montreal Clinical Trial Site, Ottawa Clinical Trial Site, Vancouver Germany
Clinical Trial Site, Berlin Clinical Trial Site, Bochum Clinical Trial Site, Bonn Clinical Trial Site, Dresden Clinical Trial Site, Münster Clinical Trial Site, Taufkirchen United Kingdom
Clinical Trial Site, Birmingham Clinical Trial Site, Cambridge Clinical Trial Site, Cardiff Clinical Trial Site, Glasgow Clinical Trial Site, Greater Manchester Clinical Trial Site, London Clinical Trial Site, Oxford Clinical Trial Site, Plymouth